Anthropic’s Claude autonomously designs protein binders, achieving 27% hit rate

Anthropic just turned its chatbot into a drug designer. The company demonstrated that Claude can autonomously design protein binders that actually work in the lab, reporting a 27% experimental hit rate for de novo protein binders across most targets tested. That number might sound modest until you consider what it represents: an AI system generating entirely new protein structures from scratch, then having those designs validated through wet-lab experiments. In the broader landscape of AI protein design, experimental hit rates range from roughly 10% to 64% for mini-binders, putting Claude’s results squarely in competitive territory. Claude Science and the 60-database backbone The results come through Claude Science, a comprehensive AI workbench Anthropic launched on June 30, 2026. The platform is built to handle end-to-end protein design workflows, from initial target nomination and structure handling all the way through candidate evaluation. Under the hood, Claude generates its de novo designs using established computational biology pipelines including RFdiffusion, ProteinMPNN, and AlphaFold. The platform integrates more than 60 scientific databases and tools, giving the model acc...